WO2020053795A3 - Process for the preparation of acalabrutinib and its intermediates - Google Patents

Process for the preparation of acalabrutinib and its intermediates Download PDF

Info

Publication number
WO2020053795A3
WO2020053795A3 PCT/IB2019/057678 IB2019057678W WO2020053795A3 WO 2020053795 A3 WO2020053795 A3 WO 2020053795A3 IB 2019057678 W IB2019057678 W IB 2019057678W WO 2020053795 A3 WO2020053795 A3 WO 2020053795A3
Authority
WO
WIPO (PCT)
Prior art keywords
acalabrutinib
preparation
intermediates
present
relates
Prior art date
Application number
PCT/IB2019/057678
Other languages
French (fr)
Other versions
WO2020053795A2 (en
Inventor
Chandan Kumar Gupta
Hemant Kumar Singh
Navdeep DHIMAN
Sunil Sanghani
Govind Singh
Saswata Lahiri
Walter Cabri
Nitin Gupta
Original Assignee
Fresenius Kabi Oncology Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fresenius Kabi Oncology Ltd. filed Critical Fresenius Kabi Oncology Ltd.
Publication of WO2020053795A2 publication Critical patent/WO2020053795A2/en
Publication of WO2020053795A3 publication Critical patent/WO2020053795A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides an improved and industrially viable process for the preparation of Acalabrutinib and its intermediates in high yield and eliminating the use of time-consuming purification process. The present invention also relates to the purification of (S)-4-(8-Amino-3-(pyrrolidin-2-yl)imidazo[1,5-alpyrazin-1-yl)-N-(pyridin-2-yl) benzamide, a key intermediate for the preparation of Acalabrutinib. Further present invention relates to new polymorphic form of Acalabrutinib.
PCT/IB2019/057678 2018-09-13 2019-09-12 Process for the preparation of acalabrutinib and its intermediates WO2020053795A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201811034524 2018-09-13
ININ201811034524 2018-09-13

Publications (2)

Publication Number Publication Date
WO2020053795A2 WO2020053795A2 (en) 2020-03-19
WO2020053795A3 true WO2020053795A3 (en) 2020-04-30

Family

ID=68470567

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2019/057678 WO2020053795A2 (en) 2018-09-13 2019-09-12 Process for the preparation of acalabrutinib and its intermediates

Country Status (1)

Country Link
WO (1) WO2020053795A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112028896A (en) * 2020-10-14 2020-12-04 奥锐特药业(天津)有限公司 Novel crystal form of acatinib and preparation method thereof
CN114605416B (en) * 2020-12-08 2023-12-01 奥锐特药业(天津)有限公司 Preparation method of acartinib crystal form I

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013010868A1 (en) * 2011-07-19 2013-01-24 Msd Oss B.V. 4 - imidazopyridazin- 1 -yl-benzamides and 4 - imidazotriazin- 1 - yl - benzamides as btk- inhibitors
WO2017002095A1 (en) * 2015-07-02 2017-01-05 Acerta Pharma B.V. Solid forms and formulations of (s)-4-(8-amino-3-(1 -(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide
WO2018064797A1 (en) * 2016-10-05 2018-04-12 杭州领业医药科技有限公司 Crystal form of acp-196, preparation method therefor and pharmaceutical composition thereof
CN108250186A (en) * 2018-02-07 2018-07-06 杭州科巢生物科技有限公司 The synthetic method of Acalabrutinib and its intermediate
WO2018130213A1 (en) * 2017-01-16 2018-07-19 东莞市真兴贝特医药技术有限公司 Imidazopyrazine compound, preparation method therefor and use thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013010868A1 (en) * 2011-07-19 2013-01-24 Msd Oss B.V. 4 - imidazopyridazin- 1 -yl-benzamides and 4 - imidazotriazin- 1 - yl - benzamides as btk- inhibitors
WO2017002095A1 (en) * 2015-07-02 2017-01-05 Acerta Pharma B.V. Solid forms and formulations of (s)-4-(8-amino-3-(1 -(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide
WO2018064797A1 (en) * 2016-10-05 2018-04-12 杭州领业医药科技有限公司 Crystal form of acp-196, preparation method therefor and pharmaceutical composition thereof
WO2018130213A1 (en) * 2017-01-16 2018-07-19 东莞市真兴贝特医药技术有限公司 Imidazopyrazine compound, preparation method therefor and use thereof
CN108250186A (en) * 2018-02-07 2018-07-06 杭州科巢生物科技有限公司 The synthetic method of Acalabrutinib and its intermediate

Also Published As

Publication number Publication date
WO2020053795A2 (en) 2020-03-19

Similar Documents

Publication Publication Date Title
MX2019012815A (en) Process for preparing optically active 2,3-dihydrothiazolo[3,2-a] pyrimidin-4-ium compounds.
MX2014001945A (en) Process and intermediates for preparing macrolactams.
MX2021008002A (en) Novel salts and polymorphic form of bempedoic acid.
WO2018029711A3 (en) Process for the preparation of venetoclax
WO2020053795A3 (en) Process for the preparation of acalabrutinib and its intermediates
WO2012082672A3 (en) Process and intermediates for preparing macrolactams
NZ596074A (en) Process for preparation of HIV protease inhibitors via bisfuran intermediates
MX2023005704A (en) Method for producing novel nitrogen-containing compound or salt thereof, and production intermediate of same.
WO2013121436A3 (en) A process for preparation of rivaroxaban and intermediates thereof
CN107001236A8 (en) The purification process and 1,5 pentanediamines of a kind of 1,5 pentanediamine
MX2019012507A (en) Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2 -oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxaze pin-9-yl)amino)propanamide, and methods of production.
MY149058A (en) N-(2-aminophenyl)-4-[n-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (ms-275) polymorph b
MX2019003026A (en) Heteroaryl carboxamide compounds as inhibitors of ripk2.
SG11201906688VA (en) Novel ester compounds, method for the production thereof and use thereof
WO2016035007A3 (en) An improved process for the preparation of apixaban and intermediates thereof
WO2018069941A3 (en) Polymorphic forms of venetoclax
TN2021000025A1 (en) Novel heterocyclic amine derivative and pharmaceutical composition comprising same
MX2020006040A (en) Intermediates for optically active piperidine derivatives and preparation methods thereof.
WO2011128784A3 (en) Novel process for preparing highly pure tapentadol or a pharmaceutically acceptable salt thereof
WO2017134684A3 (en) A process for the preparation of ibrutinib
MY157423A (en) Production method of intermediate compound for synthesizing medicament
WO2015063795A3 (en) Novel process for preparation of optically pure norephedrine and its derivatives
EA202190557A1 (en) METHODS FOR PREPARING 4- {8-AMINO-3 - [(2S) -1- (BUT-2-INOL) PYRROLIDIN-2-YL] IMIDAZO [1,5-a] PYRAZIN-1-YL} -N- (PYRIDINE -2-IL) BENZAMIDE
WO2016084100A3 (en) Novel and efficient method for large scale synthesis of romidepsin
WO2009038328A3 (en) Acid addition salts of synthetic intermediates for carbapenem antibiotics and processes for preparing the same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19798716

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19798716

Country of ref document: EP

Kind code of ref document: A2